<DOC>
	<DOCNO>NCT01418677</DOCNO>
	<brief_summary>This open-label non-randomized study subject advance metastatic solid tumor longer respond available therapy . HALAVEN administer subject Days 1 8 21-day cycle .</brief_summary>
	<brief_title>An Open-Label Study Assess Pharmacokinetics Safety HALAVEN Subjects With Cancer Who Also Have Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Histologically cytologically confirm advanced solid tumor progress follow standard therapy standard therapy exists ( include surgery radiation therapy ) . Renal function must fall one follow category : Normal function creatinine clearance great equal 80 mL/min . Moderate impairment creatinine clearance &gt; 30 50 mL/min . Severe impairment creatinine clearance 15 less 30 mL/min . Adequate liver function evidence bilirubin less equal 1.5 time upper limit normal ( ULN ) alkaline phosphatase ( ALP ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3 time ULN ( case liver metastasis le equal 5 time ULN ) . In case ALP &gt; 3 time ULN ( absence liver metastasis ) &gt; 5 time ULN ( presence liver metastasis ) , subject also know bone metastasis , liver specific ALP must separate total use ass liver function instead total ALP . Subjects mild renal impairment ( creatinine clearance great 50 less 80 mL/min ) . Subjects end stage renal disease ( creatinine clearance le 15 mL/min dialysis ) . Subjects hypersensitivity halichondrin B and/or halichondrin B chemical derivative . Subjects prior participation HALAVEN clinical study , even previously assign HALAVEN treatment . Radiation therapy encompass &gt; 30 % bone marrow . Subjects organ allograft require immunosuppression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Unspecified Advance Solid Tumor , Protocol Specific</keyword>
</DOC>